Outcomes in Relapsed Graves' Disease Patients Following Radioiodine or Prolonged Low Dose of Methimazole Treatment

Thyroid ◽  
2015 ◽  
Vol 25 (12) ◽  
pp. 1282-1290 ◽  
Author(s):  
Danilo Villagelin ◽  
João H. Romaldini ◽  
Roberto B. Santos ◽  
Ana B.B.P. Milkos ◽  
Laura S. Ward
Keyword(s):  
Low Dose ◽  
Graves Disease

Low Dose Radioiodine Therapy for Graves' disease: comparison of outcomes following administration of different doses across two centres

2018 ◽  
Author(s):  
Natasha Sawhney ◽  
Carmen Diaz-Ortega ◽  
Sam Philip ◽  
Fraser Gibb ◽  
Prakash Abraham ◽  
...  
Keyword(s):  
Low Dose ◽  
Radioiodine Therapy ◽  
Graves Disease ◽  
Different Doses

scholarly journals Prognostic Value ofTc99m-Pertechnetate Thyroid Scintigraphy in Radioiodine Therapy in a Cohort of Chinese Graves’ Disease Patients: A Pilot Clinical Study

2015 ◽  
Vol 2015 ◽  
pp. 1-4 ◽  
Author(s):  
Haifeng Hou ◽  
Shu Hu ◽  
Rong Fan ◽  
Wen Sun ◽  
Xiaofei Zhang ◽  
...  
Keyword(s):  
Single Dose ◽  
Prognostic Value ◽  
Low Dose ◽  
Radioiodine Therapy ◽  
Treatment Success ◽  
Serum Levels ◽  
Graves Disease ◽  
Thyroid Scintigraphy ◽  
Thyroid Mass ◽  
Pilot Clinical Study

Objectives. This study is to assess the prognostic value ofTc99m-pertechnetate thyroid scintigraphy for predicting the outcomes of fixed low dose of radioiodine therapy (RIT) in a cohort of Chinese Graves’ disease (GD) patients.Materials and Methods. This is a retrospective study of GD patients who received RIT with a single dose of radioiodine (5 mCi). All the patients receivedTc99m-pertechnetate thyroid scintigraphy prior to RIT. Thyroid mass,Tc99m-pertechnetate uptake, gender, age at diagnosis, duration of the disease, ophthalmopathy, and serum levels of FT4, FT3, TT4, and TT3 prior to RIT were analyzed as potential interference factors for outcomes of RIT.Results. One hundred and eighteen GD patients who completed RIT were followed up for 12 months. The outcomes (euthyroidism, hypothyroidism, and hyperthyroidism) were found to be significantly associated with thyroid mass andTc99m-pertechnetate uptake. Patients with thyroid mass ≤ 40.1 g orTc99m-pertechnetate uptake ≤ 15.2% had higher treatment success.Conclusions. A fixed low dose of 5 mCi radioiodine seems to be practical and effective for the treatment of Chinese GD patients with thyroid mass ≤ 40.1 g andTc99m-pertechnetate uptake ≤ 15.2%. This study demonstratesTc99m-pertechnetate thyroid scintigraphy is an important prognostic factor for predicting the outcomes of RIT.

Low-Dose Anti-Thyroid Medication in Graves Disease: Assessment of the Efficacy Based on a Long-Term Follow-Up (Interim Report)

2011 ◽  
pp. P1-684-P1-684
Author(s):  
Hamid Reza Bazrafshan ◽  
Friedrich Fitz ◽  
Martin Steinmair ◽  
Clemens Reichl ◽  
Mohsen Beheshti ◽  
...  
Keyword(s):  
Low Dose ◽  
Disease Assessment ◽  
Graves Disease ◽  
Interim Report ◽  
Thyroid Medication ◽  
Long Term Follow Up

scholarly journals Low-Dose 131I in Treatment of Graves' Disease

1985 ◽  
Vol 78 (3) ◽  
pp. 197-202 ◽  
Author(s):  
C P Lowdell ◽  
G S Spathis ◽  
D O Cosgrove ◽  
H J Dobbs ◽  
V R McCready ◽  
...  
Keyword(s):  
Low Dose ◽  
Graves Disease

scholarly journals Radiotherapy for Graves’ disease. The possible role of low-dose radiotherapy

2016 ◽  
Vol 21 (3) ◽  
pp. 213-218 ◽  
Author(s):  
Meritxell Arenas ◽  
Sebastià Sabater ◽  
Pedro Lara Jiménez ◽  
Àngels Rovirosa ◽  
Albert Biete ◽  
...  
Keyword(s):  
Low Dose ◽  
Graves Disease ◽  
Low Dose Radiotherapy

scholarly journals Low-Dose Immunization with Adenovirus Expressing the Thyroid-Stimulating Hormone Receptor A-Subunit Deviates the Antibody Response toward That of Autoantibodies in Human Graves’ Disease

Endocrinology ◽  
2004 ◽  
Vol 145 (1) ◽  
pp. 228-233 ◽  
Author(s):  
Chun-Rong Chen ◽  
Pavel Pichurin ◽  
Gregorio D. Chazenbalk ◽  
Holly Aliesky ◽  
Yuji Nagayama ◽  
...  
Keyword(s):  
Antibody Response ◽  
Low Dose ◽  
Standard Dose ◽  
Thyroid Stimulating Hormone ◽  
Similar Proportion ◽  
Graves Disease ◽  
Antibody Activity ◽  
Blocking Antibody ◽  
A Subunit ◽  
Viral Dose

Abstract Immunization with adenovirus expressing the TSH receptor (TSHR) induces hyperthyroidism in 25–50% of mice. Even more effective is immunization with a TSHR A-subunit adenovirus (65–84% hyperthyroidism). Nevertheless, TSHR antibody characteristics in these mice do not mimic accurately those of autoantibodies in typical Graves’ patients, with a marked TSH-blocking antibody response. We hypothesized that this suboptimal antibody response was consequent to the standard dose of TSHR-adenovirus providing too great an immune stimulus. To test this hypothesis, we compared BALB/c mice immunized with the usual number (1011) and with far fewer viral particles (109 and 107). Regardless of viral dose, hyperthyroidism developed in a similar proportion (68–80%) of mice. We then examined the qualitative nature of TSHR antibodies in each group. Sera from all mice had TSH binding-inhibitory (TBI) activity after the second immunization, with TBI values in proportion to the viral dose. After the third injection, all groups had near-maximal TBI values. Remarkably, in confirmation of our hypothesis, immunization with progressively lower viral doses generated TSHR antibodies approaching the characteristics of autoantibodies in human Graves’ disease as follows: 1) lower TSHR antibody titers on ELISA and 2) lower TSH-blocking antibody activity without decrease in thyroid-stimulating antibody activity. In summary, low-dose immunization with adenovirus expressing the free TSHR A-subunit provides an induced animal model with a high prevalence of hyperthyroidism as well as TSHR antibodies more closely resembling autoantibodies in Graves’ disease.

Sign in / Sign up

Export Citation Format

Share Document